Kanker paru merupakan salah satu penyebab utama kematian akibat kanker di Indonesia dengan beban biaya pengobatan yang tinggi. Non-Small Cell Lung Cancer (NSCLC) merupakan jenis kanker paru yang paling banyak ditemukan, mencakup sekitar 80–85?ri seluruh kasus. Perbedaan stadium penyakit pada pasien NSCLC dapat memengaruhi besarnya biaya pengobatan yang harus ditanggung oleh pasien maupun penyedia layanan kesehatan. Oleh karena itu, penelitian ini bertujuan untuk menganalisis perbedaan biaya medis langsung pasien NSCLC berdasarkan stadium penyakit pada pelayanan rawat jalan dan rawat inap.
Penelitian ini menggunakan desain observasional analitik dengan pendekatan retrospektif. Data diperoleh dari rekam medis dan catatan keuangan pasien NSCLC sebanyak 98 pasien periode Januari–Desember 2025 di RSUP Dr. Sardjito. Analisis data dilakukan dengan pendekatan cross-sectional. Analisis deskriptif digunakan untuk menggambarkan karakteristik pasien serta distribusi biaya medis langsung pada pelayanan rawat jalan dan rawat inap. Uji Mann–Whitney digunakan untuk menganalisis perbedaan rata-rata biaya medis langsung antar kelompok stadium penyakit.
Hasil penelitian menunjukkan bahwa pasien didominasi oleh stadium lanjut (III dan IV). Terdapat variasi biaya medis langsung antar stadium, dengan kecenderungan biaya lebih tinggi pada stadium lanjut. Rata-rata biaya per episode rawat jalan sebesar Rp5.206.275 ± Rp7.401.707, sedangkan rawat inap sebesar Rp22.399.448 ± Rp44.520.433. Uji Mann–Whitney menunjukkan tidak terdapat perbedaan signifikan pada rawat jalan (p > 0,05), namun terdapat perbedaan signifikan pada rawat inap (p < 0>
Lung cancer is one of the leading causes of cancer-related mortality in Indonesia and imposes a substantial economic burden due to high treatment costs. Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 80–85% of all cases. Differences in disease stage among patients with NSCLC may affect the magnitude of treatment costs borne by both patients and healthcare providers. Therefore, this study aimed to analyze differences in direct medical costs of NSCLC patients based on disease stage in outpatient and inpatient services.
This study employed an analytical observational design with a retrospective approach. Data were obtained from the medical records and financial records of 98 NSCLC patients during the period of January–December 2025 at RSUP Dr. Sardjito. Data analysis was conducted using a cross-sectional approach. Descriptive analysis was used to describe patient characteristics and the distribution of direct medical costs in outpatient and inpatient services. The Mann–Whitney test was used to analyze differences in the average direct medical costs between disease stage groups.
The results showed that most patients were in advanced stages (III and IV). Variations in direct medical costs were observed across stages, with a tendency for higher costs in advanced stages. The average cost per outpatient episode was IDR 5,206,275 ± 7,401,707, while the average inpatient cost was IDR 22,399,448 ± 44,520,433. The Mann–Whitney test showed no significant difference in outpatient services (p > 0.05), but a significant difference was found in inpatient services (p< 0>
Kata Kunci :
Non-Small Cell Lung Cancer (NSCLC), biaya terapi, stadium kanker, biaya medis langsung
